Omnicell offers a compelling combination of 33% analyst upside, a PEG of 0.05, and free cash flow conversion of 551% relative to net income alongside a Piotroski F-Score of 8/9, but momentum has slipped below the minimum threshold and the stock trades well above the options market's max pain level of $35.
Thesis pillars
- Exceptional Fcf Piotroski Quality↓Deteriorating
- Analyst Upside Peg Value↑Improving
- Earnings Beat Streak↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Omnicell, Inc. (OMCL) Stock Analysis
Inst Constrain edge
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $35.46, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Negative momentum.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an... Read more
Hold if already holding. Not a fresh buy at $35.46, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.7/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, earnings proximity 91d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated Nov 3, 2026Recent Developments — Omnicell, Inc.
Latest news
- NEWS BofA Securities Adjusts Price Target on Omnicell to $68 From $70 — fiscal.ai Nov 3, 2026 negative
- NEWS Freedom Capital Markets Maintains Omnicell at Buy, Lowers Price Target to $55 — fiscal.ai Oct 31, 2026 negative
- NEWS Freedom Capital Markets Maintains Buy on Omnicell, Lowers Price Target to $55 — benzinga Oct 31, 2026 neutral
- NEWS Omnicell Q3 2026 Earnings Call Transcript — benzinga Oct 29, 2026 neutral
- NEWS Omnicell, Inc. Reports Q3 2026 Financial Results — fiscal.ai Oct 29, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-04T11:49:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-07-01Item 5.02LOWNnamdi Njoku was appointed President effective July 1, 2026, while retaining his COO role. CEO Randall Lipps stepped down from the President title but remains CEO and Chairman; no compensation changes.SEC filing →
- 2026-05-26Item 5.02LOWStockholders approved an amendment to the 2009 Equity Incentive Plan at the May 19, 2026 Annual Meeting, adding 1,600,000 shares available for issuance. Routine plan amendment, not an executive departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $35.46, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Analyst target $49.96 (+40.9%), stop $33.39 (−6.2%), A.R:R 4.8:1. Score 5.7/10, moderate confidence.
Analyst target: $49.96 (+40.9% upside). Analyst target $49.96 (+40.9%), stop $33.39 (−6.2%), A.R:R 4.8:1. Stop-loss: $33.39.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Negative momentum; Below 200-MA, MA slope -4.0%/30d (confirmed downtrend).
Omnicell, Inc. trades at a P/E of 36.9 (forward 17.7). TrendMatrix value score: 7.4/10. Verdict: Hold.
14 analysts rate OMCL, with a consensus score of 4.1/5. 7 analysts publish price targets averaging $57.
What does Omnicell, Inc. do?Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and...
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.